Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome

[1]  H. Döhner,et al.  A 2:1 randomized, open-label, phase II study of selinexor vs. physician’s choice in older patients with relapsed or refractory acute myeloid leukemia , 2021, Leukemia & lymphoma.

[2]  Xiwen Ma,et al.  Updated overall survival of eltanexor for the treatment of patients with hypomethylating agent refractory myelodysplastic syndrome. , 2021 .

[3]  E. Vellenga,et al.  Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial. , 2021, Blood advances.

[4]  E. Vellenga,et al.  Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS , 2021, Cancers.

[5]  A. Letai,et al.  Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. , 2020, The New England journal of medicine.

[6]  S. Bohlander,et al.  Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Sourav K. Mishra,et al.  Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. , 2020, The Lancet. Haematology.

[8]  J. Byrd,et al.  Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study , 2020, Leukemia & lymphoma.

[9]  C. Cubitt,et al.  Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia , 2019, Clinical Cancer Research.

[10]  A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy , 2019, Case Medical Research.

[11]  K. Rezvani,et al.  Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid Leukemia. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[12]  Shuang Liu,et al.  Inhibition of XPO1 enhances cell death induced by ABT‐199 in acute myeloid leukaemia via Mcl‐1 , 2018, Journal of cellular and molecular medicine.

[13]  Robert K. Stuart,et al.  CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  R. Garzon,et al.  A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia. , 2017, Blood.

[15]  Bob Löwenberg,et al.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.

[16]  R. Garzon,et al.  XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus , 2016, Clinical Cancer Research.

[17]  A. Letai,et al.  Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice , 2016, Leukemia.

[18]  Robert K Hills,et al.  Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Bob Löwenberg,et al.  High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  G. Juliusson.  Older patients with acute myeloid leukemia benefit from intensive chemotherapy: an update from the Swedish Acute Leukemia Registry. , 2011, Clinical Lymphoma, Myeloma & Leukemia.